Haleon plc ADR (HLN) is overvalued and Teva- Pharmaceutical Industries Ltd (TEVA) is overvalued.
Both trade above our estimate of their intrinsic value. HLN is the closer of the two: -22%, against -110% for TEVA.
Values as of the 17 Nov 2026 close.
Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $7.44; the price of $9.05 is 22% above that value, and 76% of that value comes from beyond year five.
Leak Score: free with an account
Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $20.28; the price of $42.62 is 110% above that value, and 73% of that value comes from beyond year five.
Leak Score: free with an account
| Metric | HLN | TEVA |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $9.05 | $42.62 |
| Intrinsic value | $7.44 | $20.28 |
| Margin of safety | -22% | -110% |
| Market cap | $39.7B | $49.7B |
| Revenue growth, 5 years | 2.8% | 0.8% |
| Operating margin | 23.3% | 19.2% |
| Net margin | 14.6% | 2.9% |
| Return on equity | 10.0% | 6.7% |
| Debt to equity | 0.50 | 2.13 |
| P/E | 18.6x | 100.3x |
| Forward P/E | 15.2x | 13.7x |
| P/B | 1.8x | 6.2x |
| Dividend yield | 2.4% | — |